Segment and Other Information

3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Segment and Other Information

Segment and Other Information

Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker, or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment which is the development and commercialization of specialty pharmaceutical products. The following table presents a summary of total revenues (in thousands):

	Three Months Ended March 31,
	2014		2013
Xyrem® (sodium oxybate) oral solution	$	160,378	$	117,526
Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase®	46,920		41,816
Defitelio® (defibrotide)/defibrotide	12,209		—
Prialt® (ziconotide) intrathecal infusion	4,309		4,986
Psychiatry	9,866		17,650
Other	11,304		12,674
Product sales, net	244,986		194,652
Royalties and contract revenues	1,933		1,585
Total revenues	$	246,919	$	196,237

The following table presents a summary of total revenues attributed to geographic sources (in thousands):

	Three Months Ended March 31,
	2014		2013
United States	$	214,956	$	176,911
Europe	24,343		14,362
All other	7,620		4,964
Total revenues	$	246,919	$	196,237

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues:

	Three Months Ended March 31,
	2014		2013
Express Scripts	65	%	60	%
Accredo	15	%	17	%

The following table presents total long-lived assets by location (in thousands):

	March 31, 2014		December 31, 2013
Ireland	$	11,161	$	5,799
Italy	10,283		—
United States	7,765		7,734
Other	839		713
Total long-lived assets (1)	$	30,048	$	14,246

_________________________

(1)     Long-lived assets consist of property and equipment.